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Evaluation of earlier versus later dietary
management in long-chain 3-hydroxyacyl-
CoA dehydrogenase or mitochondrial
trifunctional protein deficiency: a
systematic review
Hannah Fraser1* , Julia Geppert1, Rebecca Johnson2, Samantha Johnson3, Martin Connock1, Aileen Clarke1,
Sian Taylor-Phillips1 and Chris Stinton1
Abstract
Background: Mitochondrial trifunctional protein (MTP) and long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD)
deficiencies are rare fatty acid β-oxidation disorders. Without dietary management the conditions are life-
threatening. We conducted a systematic review to investigate whether pre-symptomatic dietary management
following newborn screening provides better outcomes than treatment following symptomatic detection.
Methods: We searched Web of Science, Medline, Pre-Medline, Embase and the Cochrane Library up to 23rd April
2018. Two reviewers independently screened titles, abstracts and full texts for eligibility and quality appraised the
studies. Data extraction was performed by one reviewer and checked by another.
Results: We included 13 articles out of 7483 unique records. The 13 articles reported on 11 patient groups,
including 174 people with LCHAD deficiency, 18 people with MTP deficiency and 12 people with undifferentiated
LCHAD/MTP deficiency. Study quality was moderate to weak in all studies. Included studies suggested fewer heart
and liver problems in screen-detected patients, but inconsistent results for mortality. Follow up analyses compared
long-term outcomes of (1) pre-symptomatically versus symptomatically treated patients, (2) screened versus
unscreened patients, and (3) asymptomatic screen-detected, symptomatic screen-detected, and clinically diagnosed
patients in each study. For follow up analyses 1 and 2, we found few statistically significant differences in the long-
term outcomes. For follow up analysis 3 we found a significant difference for only one comparison, in the
incidence of cardiomyopathy between the three groups.
Conclusions: There is some evidence that dietary management following screen-detection might be associated
with a lower incidence of some LCHAD and MTP deficiency-related complications. However, the evidence base is
limited by small study sizes, quality issues and risk of confounding. An internationally collaborative research effort is
needed to fully examine the risks and the benefits to pre-emptive dietary management with particular attention
paid to disease severity and treatment group.
Keywords: Systematic review, Long-chain 3-hydroxyacyl-CoA dehydrogenase, Mitochondrial trifunctional protein
deficiency, Inborn errors of metabolism, Long-term outcomes, Newborn screening
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Introduction
Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD)
deficiency and mitochondrial trifunctional protein defi-
ciency (MTPD) are rare autosomal recessive fatty acid β-
oxidation disorders. Combined, they have an estimated
prevalence of 1.02 per 100,000 live births worldwide [1].
MTP deficiency can be caused by either mutations in the
HADHB gene or the HADHA gene, whilst LCHAD defi-
ciency is only caused by mutations in the HADHA gene
[2]. The HADHA gene encodes for the alpha subunit of
the mitochondrial trifunctional protein (MTP) which is
composed of four alpha and four beta subunits and which
acts as a catalyst in three activities (as a hydratase, a
dehydrogenase, and a thiolase) in the mitochondrial β-
oxidation of long-chain fatty acids. In LCHAD deficiency
(LCHADD), mutations occur within the alpha subunit of
the LCHAD enzyme, with normal activity in the other two
MTP enzymes. In MTP deficiency, mutations result in
deficient activities in the two other MTP enzymes (long-
chain enoyl-CoA hydratase and long-chain 3-oxoacyl-
CoA thiolase) [3].
Common signs and symptoms of LCHAD/MTP defi-
ciencies include fatigue, rhabdomyolysis and hypoketotic
hypoglycaemia. Long-term complications include cardio-
myopathy, organ failure and death. Clinical presentations
of LCHADD/MTPD are variable, even in cases with the
same underlying mutation [4]. Three clinical phenotypes
have been described: (1) an early-onset severe form
which presents from birth/a few days after birth and can
result in sudden-infant death from cardiomyopathy or
organ failure, (2) an infant-onset form which is often in-
duced by infection and which causes, for example, hypo-
ketotic hypoglycaemia, and (3) a later-onset myopathic
form which is induced by exercise or illness and often
presents as muscular problems, fatigue and rhabdo-
myolysis [5–7]. It has been suggested that people with
MTP deficiency are more likely to have the early-onset
severe form than those with LCHADD [8, 9]. Con-
versely, people with LCHADD are more likely to have
the infant-onset form than those with MTP deficiency
[10]. There may also be differences in long-term out-
comes between the two conditions; retinopathy may be
more common in people with LCHADD [11, 12] and
peripheral neuropathy more common in people with
MTPD [12].
Treatment for LCHADD and MTPD consists of a strict
dietary management, which can include eating frequently,
a low-fat and high-carbohydrate food plan, and/or taking
supplements such as medium-chain triglycerides (MCT)
[6]. It has been suggested that earlier treatment might
result in better long-term outcomes than later treatment
[6, 13]. Newborn screening is one method by which earlier
diagnosis can be achieved. LCHAD/MTP deficiencies are
already included in the newborn screening programmes of
European countries such as Germany, Austria, Spain
and Denmark [8, 13–15] as well as across North
America [16, 17]. A key criterion to assess screening
programmes is that there should be evidence that treat-
ment at a pre-symptomatic (rather than just ‘early’) stage
leads to better outcomes for individuals compared to those
who are clinically detected following the onset of symp-
toms. To date, no systematic reviews have been undertaken
which synthesise and quality appraise the evidence on
detection and age at treatment initiation and their effects
on long-term outcomes of LCHADD/MTPD patients.
Therefore, the aim of this review is to investigate whether
pre-symptomatic dietary management (following universal
newborn screening, cascade testing due to previously
affected sibling(s), or incidental detection) provides better
long-term outcomes for patients with LCHAD/MTP defi-
ciencies than later dietary management (after symptomatic
presentation).
Methods
The protocol is registered at the PROSPERO Inter-
national Prospective Register of Systematic Reviews
(registration number CRD42018094356).
Search strategy
Systematic literature searches were undertaken in the
following electronic databases: Web of Science (Core Col-
lection), Medline (Ovid), Medline In-Process & Other
Non-Indexed Citations (Ovid), Embase (Ovid), and the
Cochrane Library (Wiley). We searched for terms relating
to the condition such as MTP and LCHAD deficiencies as
well as general terms such as fatty acid oxidation disorders
and inborn errors of lipid metabolism (the full electronic
search strategy can be found in Additional file 1). We also
examined the reference lists of included studies and previ-
ous relevant systematic reviews. The search was conducted
on 23rd April 2018. No date limits or language limits were
applied.
Eligibility criteria
We included articles that investigated people with genet-
ically confirmed LCHADD or MTPD comparing any
outcome after dietary management and other nutritional
strategies (e.g. MCT supplementation) following (1) pre-
symptomatic detection by screening (universal newborn
screening, cascade testing or incidental detection) with
(2) treatment following presentation with symptoms
(either before or after the screening period).
We included any study design in humans that reported
comparative data. Non-human studies, letters, editorials,
communications, grey literature and conference ab-
stracts were excluded. Studies of fatty acid β-oxidation
disorders where data from people with mitochondrial
trifunctional protein disorders could not be separated
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from data on other fatty acid oxidation disorders (e.g.
multiple acyl-CoA dehydrogenase and very long-chain
acyl-CoA dehydrogenase deficiencies) and studies where
more than 10% of the sample did not meet our inclusion
criteria, were also excluded. Systematic reviews were ex-
cluded but their references were checked for inclusion.
Study selection and data extraction
The titles, abstracts, and full texts of papers were assessed
independently by two reviewers. Data were extracted by
one reviewer and checked by a second using a piloted
electronic data collection form (Additional file 2). Dis-
agreements were resolved through discussion, with the in-
volvement of a third reviewer when required.
Quality appraisal
Quality appraisal was undertaken independently by two
reviewers; disagreements were resolved via consensus or
a third reviewer. We used the Effective Public Health
Practice Project (EPHPP) quality assessment tool for
quantitative studies [18]. The EPHPP has six domains:
selection bias, study design, confounders, blinding, data
collection methods, withdrawals and dropouts. Each
study is given an overall rating for quality of weak (two
or more weak domains), moderate (one weak domain)
or strong (no weak domains) [19].
Data summary and synthesis
A narrative synthesis of study characteristics and out-
comes is provided for all included studies.
There were differences in how ‘early’ was defined
across studies. In the majority of cases ‘early’ was defined
as screen-detected and asymptomatic, and ‘late’ was
defined as clinically detected after presenting with symp-
toms. However, there is a subgroup of patients who
present with symptoms at the time of screening. Studies
varied in whether they included this group within the
‘screened’ group, or within a ‘symptomatic at diagnosis’
group. Three planned a priori follow up analyses were
undertaken to address concerns about the applicability
of including pre-screening symptomatic patients in the
screen-detected group as well as possible confounding
factors. These follow up analyses considered different
subsets of the available individual patient data of the in-
cluded articles:
(1) Asymptomatically vs symptomatically detected
patients.
In this comparison, we allocated cases who were symp-
tomatic within the first few days of life (so at the time of
NBS screening) to the ‘symptomatically detected’ group
and compared them to patients who were ‘asymptomatic’
at the time of NBS screening or cascade testing due to
previously affected siblings. This may bias findings in
favour of screening as these early symptomatic cases
might have a more severe spectrum of disease.
(2) Screened vs unscreened patients.
In this comparison, the ‘screened’ group includes all
patients identified via NBS screening (irrespective of
being symptomatic at the time of screening or not) and
patients identified via cascade testing due to previously
affected siblings. Allocating the severe cases who have
symptoms at the time of newborn screening to the
‘screened’ group biases against screening because in
current practice these patients would undergo diagnostic
testing anyway, so they would not actually benefit from
universal newborn screening. In addition, the compari-
son might be biased in favour of screening due to most
of the ‘unscreened’ patients being born prior to imple-
mentation of universal newborn screening and therefore
being older than screened patients and experiencing a
historical health care pathway.
(3) People who were asymptomatic at screening, symp-
tomatic at screening, and those who were clinically de-
tected in the absence of screening or who were clinically
detected following false negative screening results.
To allow for the potential bias of including the severe
forms of the diseases which present prior to screening,
the third analysis analysed the three possible groups
separately - asymptomatic at screening, symptomatic at
screening and those with late clinical diagnosis due to
symptoms.
In the follow up analyses, frequencies of complications
between the groups were compared using the chi-square
test; in cases of expected values smaller than 5, a Fisher’s
exact test was used. All chi-square and Fisher’s exact tests
were performed in IBM SPSS Statistics 24. Forest plots
were prepared using Stata version 15.0 (Statacorp, College
Station, TX, USA) with the metaprop command [20].
Results
Searching, sifting, and sorting
Database searches yielded 7483 results, of which 313 full
texts were assessed, and 12 were judged to be relevant to
this review. An additional article was identified from a
search for a related review all other references raised by
this search were checked and none were deemed eligible
for inclusion. Overall, 13 articles were ultimately in-
cluded. Details regarding exclusions at each stage can be
found in the PRISMA diagram (Fig. 1). Reasons for ex-
clusions of full texts can be found in Additional file 3.
Characteristics of included studies
The main characteristics of included studies are sum-
marised in Table 1. Thirteen papers (reporting on 11 pa-
tient groups) compared outcomes for screen-detected
and early-treated patients versus unscreened and later-
treated LCHADD/MTPD patients [6, 9, 13, 15, 21–29].
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The number of LCHADD/MTPD patients included per
analysis ranged from five people from a single clinic in
Utah, USA [26] to 59 from two centres in Poland [29]. A
total of 174 people with LCHAD deficiency, 18 people
with MTPD and 12 people with undifferentiated LCHAD/
MTPD were included across all the studies.
Seven of the eleven included studies were retrospective
cohort studies [6, 9, 13, 25, 26, 28, 29]. Three studies (re-
ported in five papers) were prospective studies [15, 21–24]
and one was a randomised controlled trial (RCT) for a
drug treatment which has been analysed as a cohort study
in this review [27]. The shortest study duration was three
years [9] and the longest period of follow up was up to 17
years [29]. One study did not report follow up time [6].
Type of dietary management was not specified in three of
the studies [9, 15, 29]. In the remaining eight studies all
received a diet of low fat intake with essential fatty acid
supplementation. Whether patients were given docosa-
hexaenoic acid (DHA), carnitine, or MCT (e.g.
Triheptanoin) supplements varied across studies and
across patients within studies. Five papers (reporting on
three patient groups) reported on dietary compliance [21–
24, 26].
Quality appraisal
The quality assessment of included studies can be found
in Fig. 2 and Additional file 4. Overall, the methodo-
logical quality was judged as weak in seven studies (8
papers), with two or more domains receiving a weak rat-
ing [6, 9, 21, 22, 24, 26, 27, 29]. The five remaining stud-
ies were rated as moderate, with one domain receiving a
weak rating [13, 15, 23, 25, 28].
There was a high risk of selection bias in three studies
[6, 26, 27]. In all three studies it was unclear if the indi-
viduals selected to participate in the study were representa-
tive of the target population as it was not specified if all
clinic patients or a random sample were included. Study
Fig. 1 PRISMA flow diagram of records through the systematic review
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Table 1 Characteristics of included studies
Study Study design Participants Treatment
Swedish
Cohort
studies
Fahnehjelm
2008 [21]
Cohort study
Average follow-up time:
median 7.5 years
(range 2.3–14.8 years)
Study period: Not reported
Study setting: Karolinska
University Hospital and
Uppsala University
Hospital, Sweden
Number of centres: 2
n = 10, 10/10 LCHADD.
Asymptomatic screened: n = 1
(cascade testing).
Age of diagnosis/treatment: First days of life
Clinical presentation with symptoms: n = 9
Clinical symptoms (S) but no acute illness: n = 4
Severe symptoms (SS) (elevated liver enzymes
and cardiomyopathy and /or seizures): n = 5
Age of diagnosis/treatment:
0-1 m (n = 1), 1-6 m (n = 2), > 6 m (n = 6)
All patients received a dietary
treatment of low fat intake and
essential fatty acid supplementation.
All children also received DHA.
Compliance of treatment is
not reported.
Fahnehjelm
2016 [22]
Cohort study. Prospective
and retrospective
data collection
Average follow up time:
median 15 years (range 3–
26 years).
Time period/study duration:
Not reported
Patients diagnosed between
1990 to using the same
treatment guidelines
Study setting: Karolinska
University Hospital and
Uppsala University Hospital,
Sweden
Number of centres: 2
n = 12, 12/12 LCHADD.
Asymptomatic screened n = 3
(2 by NBS, 1 unspecified).
Age of diagnosis/treatment: First days of life
Clinical presentation with symptoms: n = 9
Clinical symptoms (S) but no acute illness: n = 4
Severe symptoms (SS) (elevated liver enzymes
and cardiomyopathy and /or seizures): n = 5
Age of diagnosis/treatment:
0-1 m (n = 1), 1-6 m (n = 2), > 6 m (n = 6)
All patients received a dietary
treatment of low fat intake and
essential fatty acid supplementation.
11/12 had DHA.
8/12 continuous night feeds.
Dietary compliance:
Asymptomatic screened: all
acceptable
S clinical:
1/4 (25%) poor, 3/4 (75%)
acceptable
SS clinical:
3/5 (60%) poor, 2/5 (40%)
acceptable
Haglind
2013 [23]
Cohort study, retrospective
data collection of
medical reviews
Time period/study duration:
Not reported
Patients aged up to 20 years
Study setting: Karolinska
University Hospital and
Uppsala University Hospital,
Sweden
Number of centres: 2
n = 10, 10/10 LCHADD.
Asymptomatic screened: n = 1
(cascade testing).
Age of diagnosis/treatment: 2 days
Clinical presentation with symptoms: n = 9
Clinical symptoms (S) but no acute illness: n = 4
Severe symptoms (SS) (elevated liver enzymes
and cardiomyopathy and / or seizures): n = 5
Age of diagnosis/treatment:
mean 6.1 months (up to 13 m)
8/10 received DHA.
9/10 had a PEG with continuous
night feeds.
9/10 received MCT fat, vitamins,
minerals, and trace elements.
Fasting limited to 3–4 h.
2/10 uncooked corn starch.
1 had carnitine deficiency so
given carnitine supplements of
25-50 mg/kg/day.
Did not record compliance.
Immonen 2016 [24] Prospective cohort (followed
prospectively but using
diagnosis data from
retrospectively collected
hospital records). Comparison
with historical cohort (24/28
diagnosed post mortem)
Follow-up time (age of
patients at the end of the
study): 1–11 years
Time period: 1997–2010
Study setting: Hospitals in
Finland
Number of centres: NR
n = 16, 16/16 LCHADD.
Asymptomatic screened: n = 1 (cascade testing)
Age at treatment: Birth
Symptomatic clinical: n = 15
Age at presentation:
Birth to 0.42 years (~ 5 months). Mean 0.27 years.
Age at diagnosis:
Up to 6 months
Age at treatment initiation: 1–
30 days of diagnosis
All patients in both groups
received a low-fat diet, MCT,
essential fatty acids and DHA
(this was 10 clinical patients as
the remainder were not alive).
Fasting of more than 3 or 4 h
avoided in infancy and childhood.
Good compliance of diet in
9/11 patients.
Sperk 2010 [9] Case series (6 cases) – clinical
histories obtained from referring
physicians
Maximum follow up until age 5
years
Study duration: 3 years
Study setting: University
Children’s hospital, Düsseldorf,
Germany
Number of centres: 1
n = 6, 3/6 LCHADD, 3/6 MTPD.
Asymptomatic screened: n = 3
(1 LCHADD, 2 MPTD)
All diagnosed and began treatment 4–5 days
of age
Symptomatic screened: n = 3 (2 LCHADD, 1 MTPD)
Type of treatment not reported.
Dietary adherence not reported.
Karall 2015 [13] Retrospective cohort (review of
medical records)
Study duration: Birth – October
2013
n = 14, 14/14 LCHADD.
Asymptomatic screened: n = 6
Age at diagnosis median (range): 1.5 days
(1–10 days)
All cases received low-fat diet
and MCT supplements.
Triheptanoin was used in 2/3
symptomatic screened, 1/3 pre-
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Table 1 Characteristics of included studies (Continued)
Study Study design Participants Treatment
Follow-up time:
Range 0.9–15.4 years (median 7.8
years,
mean 6.9 years)
Study setting:
Metabolic Centres in Austria (Graz,
Innsbruck, Salzburg, Vienna) and
Germany (Munich)
Number of centres: 5
Symptomatic screened: n = 3
Age at diagnosis median (range):
15 days (15 days)
Pre-NBS clinical: n = 3
Age at diagnosis median (range):
5 months (3–20 months)
False negative (FN) screen clinical:
n = 2
Age at diagnosis median (range):
4.5 months (4–5 months)
NBS and 1/2 FN NBS.
Essential fatty acids (walnut oil)
were given to 2/3 pre-NBS
clinical cases.
DHA given to 6/6 asymptomatic
screened, 1/3 symptomatic
screened, 2/3 pre-NBS and 1/2
in FN NBS.
PEG used in 1/6 asymptomatic
screened, 1/3 pre-NBS and
1/2 FN NBS
Dietary compliance not reported.
Spiekerkoetter 2009 [6] Retrospective cohort
(questionnaire study)
Follow-up time: NR
Study setting:
Metabolic Centres, Germany/
Switzerland/
Austria/the Netherlands
Number of centres: 18
n = 75, Relevant to this review: n = 27,
20/27 LCHADD, 7/27 MTPD.
Screened: n = 10 (7 LCHADD, 3 MTPD).
Age at diagnosis: Newborn, 7/10
symptomatic at NBS.
Clinically diagnosed: n = 17
(13 LCHADD, 4 MTPD).
Age at diagnosis:
LCHADD: Median 5 months
(range 3 days – 11 years)
MTPD: median 1 year (range 1
day - 4.5 years)
Data available on LCT and MCT
in 14/27 and 17/27 of patients:
13/14 LCT intake restricted,
17/17 supplemented with MCT,
11/14 received additional
carbohydrates,
2/14 on continuous overnight
nasogastric tube feeding,
1 supplemented with DHA,
1 receiving Triheptanoin.
Dietary compliance not reported.
Boese 2016 [25] Retrospective case series (cohort)
Time period: 20/9/1994–18/8/
2015
Follow up period:
Median 5.6 years (range 0.3–20.2
years)
Study setting: Oregon Health and
Science University (OHSU) Casey
Eye Institute, USA
Number of centres: 1
n = 21, 18/21 LCHADD, 3/21 MTPD.
Screened: n = 7 (6 LCHADD, 1 MTPD).
Age at diagnosis: newborn, 1
LCHADD case symptomatic at
screening.
Clinical: n = 14 (12 LCHADD, 2 MTPD).
Age at diagnosis: median 4.5 months
(range 1 day – 3 years)
A diet low in long-chain fatty
acids and supplementation with
MCT. All subjects and/or guardians
were counselled to avoid fasting.
Some subjects were prescribed
oral carnitine supplements.
Dietary intake assessed by
24 h recall.
De Biase 2017 [26] Retrospective cohort
(chart review)
Average follow-up time: nearly
10 years (mean 9.2 years, SD 5.9
years)
Study setting:
Metabolic Clinic University of
Utah, USA
Number of centres: 1
n = 5, 4/5 LCHADD, 1/5 MTPD.
Asymptomatic screened: n = 1
(1 LCHADD)
Age at diagnosis: birth (NBS)
Symptomatic screened: n = 2
(1 LCHADD, 1 MTPD).
Age at diagnosis: birth (NBS)
Symptomatic clinical: n = 2
(2 LCHADD)
Age at diagnosis: Median 5 months
(range 4–6 months)
All patients received low-fat diet,
MCT, essential fatty acids and
carnitine. All patients bar
symptomatic clinical treated
received cornstarch.
Both screened symptomatic
cases and 1/2 clinical symptomatic
patients received DHA.
One late treated patient is noted
to have followed dietary therapy
with variable compliance.
Gillingham 2017 [27] Double blind parallel RCT
(retrospective data collected on
time of diagnosis)
Follow-up time NR
Study setting:
Oregon Health and Science
University and University of
Pittsburgh, USA
Number of centres: 2
n = 24
Included for this review: n = 12. 8/12
LCHADD,
4/12 MTPD.
Asymptomatic screened: n = 7
(5 LCHADD, 2 MTPD).
Age at diagnosis/treatment (range):
newborn (0-2 m).
Symptomatic clinical: n = 5
(3 LCHADD, 2 MTPD).
Age at diagnosis/treatment (range):
Infancy (2 m-2y) n = 4 or childhood
(2y-10y) n = 1.
All patients in the asymptomatic
and symptomatic groups received
a low-fat diet and MCT.
3/7 from the asymptomatic group
received Triheptanoin
(2 LCHADD, 1 MTP).
4/7 from the asymptomatic group
received Trioctanoin
(3 LCHADD, 1 MTP).
4/5 from the symptomatic group
received Triheptanoin
(2 LCHADD, 2 MTP)
1/5 from the symptomatic group
received Trioctanoin (1 LCHADD)
Dietary compliance not reported.
Kang 2018 [28] Retrospective cohort
Follow-up time: ~ 10 years
Time period:
May 2002 – February 2016
Study setting:
n = 22
Included for this review: n = 7
LCHADD/MTPD not differentiated
but genotypes
are suggestive of MTPD.
Screened patient educated to
avoid prolonged fasting, MCT
diet with long-chain fat restriction
Dietary compliance not reported.
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design quality was rated as moderate in all studies for hav-
ing cohort designs including one RCT of a treatment which
was effectively a cohort study for our research question.
All studies were of weak methodological quality in re-
lation to confounding, since important factors (i.e. the
presenting form of LCHAD/MTP deficiency, genotype,
compliance with treatment, co-treatment) were not con-
trolled for in study design or analysis. The quality of the
blinding methods was rated as moderate across all stud-
ies [6, 9, 13, 15, 21–29]. One of these studies was an
Table 1 Characteristics of included studies (Continued)
Study Study design Participants Treatment
Department of Medical Genetics,
Asan Medical Center Children’s
Hospital, Seoul, Korea
Number of centres: NR
Asymptomatic screened: n = 1
Symptomatic clinical: n = 6
Lund 2012 [15] Case-control study
Follow-up time: Range 2–109
months
Time period:
Feb 1st 2002 – Mar 31st 2011
(trial 2002–2009)
Study setting:
Statens Serum Institut,
Copenhagen. Cases from
Denmark, Faroe Islands and
Greenland
Number of centres: 1
n = 5
LCHADD and MTPD not differentiated.
Asymptomatic screened: n = 3
Age at diagnosis/treatment median
(range): 6 days (1d-5d)
Symptomatic clinical: n = 2
Age at diagnosis/treatment median
(range): 4.5 months (4.5 months)
Type of dietary management
not reported
Dietary compliance not reported.
Sykut-Cegielska
2011 [29]
Retrospective cohort
Follow-up time: Up to 17 years
Time period: 1992–2009
Study setting: Children’s Memorial
Health Institute and Institute of
Mother and Child Warsaw, Poland
Number of centres: 2
n = 59, 58/58 LCHADD, 1 not analysed.
Asymptomatic screened: n = 15
Age at diagnosis/treatment:
Median 14 days (range 4 days -
8 weeks)
Detected by cascade testing, TMS
pilot screening or by chance from
PKU screening.
Symptomatic clinical: n = 44
Age at diagnosis/treatment: median
(range): 6 m
(1 m-18y1m) Group includes all
those tested due
to suspicions of metabolic disorders
post mortem and diagnoses
established abroad.
Type of dietary management
not reported.
Dietary compliance not reported.
FN False Negative, LCHADD Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, MCT Medium-chain triglyceride, MTPD Mitochondrial Trifunctional Protein
Deficiency, PKU Phenylketonuria, NBS Newborn Blood Spot, PEG Percutaneous endoscopic gastrostomy, S symptomatic, SS severe symptomatic
Fig. 2 Risk of bias – authors’ judgements using the EPHPP tool
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RCT that used double blinding, but for randomisation to
a treatment drug not for method of detection [27]. In all
other studies the outcome assessor knew whether the
participants had been screened or clinically detected, but
the participants were not aware of the research ques-
tions. Data collection methods were of weak methodo-
logical quality in six of the eleven studies with the
validity and reliability of the tools used not specified
[6, 9, 24, 26, 27, 29]. There was strong methodological
quality in the ‘withdrawals and drop-outs’ domain in
ten out of the eleven studies. The only study to be
rated as moderate quality within this domain reported
full data on only 10/37 included LCHADD/MTPD pa-
tients [6].
Outcomes
This section compares outcomes following ‘early’ vs ‘late’
treatment initiation as defined in the original articles.
Therefore, the allocation of the cases with symptoms at
the time of NBS screening can differ between the stud-
ies. A wide range of outcomes was reported across the
studies. We report a narrative synthesis of the three
main groups of outcomes which were reported across
the studies (mortality, cardiac problems and liver prob-
lems). Details on other outcomes are available in Table 2
and Additional file 5.
Mortality
Mortality was reported as an outcome in six studies
[6, 9, 15, 24, 28, 29]. Overall, mortality rates across
all groups was 3/30 (10%) in the early treated groups
compared to 30/83 (36%) in the late treated groups.
In four of these studies, mortality rates were lower in
the early-treated group (range 0–20%, 1/26 total) than
in the later-treated groups (range 37.3–50%, 28/74
total) [6, 15, 24, 29]. In the remaining two studies
mortality was lower in the later-treated group (range
0–33.3%, 2/9 total) than the early-treated group
(range 33.3–100%, 2/4 total) [9, 28]. The median age at
death across the studies was 28 days in the early-treated
group (range 3 days–3months) and 4months (range 2
days–10 years 1month) in the late-treated group.
Heart related problems
Seven articles reported on heart related problems such
as cardiomyopathy, arrhythmias or cardiac complications
[6, 9, 13, 15, 24, 26, 27]. In all seven studies there were
fewer heart problems in the early treatment group
(range 0–40%, 5/31 of total patients) than the late
treated group (range 25–100%, 20/32 of total patients).
Median age at study end was reported in four of the
studies [13, 24, 26, 27]. In the early groups the median
age at study end ranged from 2 to 9 years, and in the
later treatment group the median age at study end ran-
ging from 2 to 20.5 years [13, 24, 26, 27]). However, the
only study to report age at diagnosis of cardiomyopathy
found the median age to be lower in pre-symptomatically
detected patients (4months) than in symptomatically pre-
senting patients (4.5months in the patients not detected
by newborn screening, 9 months in those with symptoms
at newborn screening, and 23months in those diagnosed
before the introduction of screening) [13].
Liver related problems and Reye syndrome
Two studies reported on the incidence of liver problems
[13, 15]. In both studies there were fewer instances of
liver related problems in the early treatment group. In
the first study there were 1/6 (16.7%) cases from the
screen-detected group (median age 5.1 years at study
end) with liver problems, whilst there were 4/8 (50%)
cases in the later treatment group (median age 9.4 years
at study end) [13]. In the second study, 0/3 people de-
tected pre-symptomatically had liver related problems
but both symptomatically presenting patients did (2/2,
age of patients at the time of the study had liver prob-
lems (age at study end was not reported in this study))
[6]. Incidence of Reye syndrome was reported in one
study [6]. There were slightly fewer cases of Reye syn-
drome in the early treatment group than the later treat-
ment group [3/10 (30%) vs 6/17 (35.3%) respectively].
Visual problems
Problems related to vision were reported in 5 studies
across 7 papers [13, 21–26]. The studies reported on
outcomes such as electroretinography (ERG) findings,
best corrected visual acuity, ocular fundi findings and
retinopathy. One study (across 2 papers) reported on
ERG findings [21, 22]. One out of 2 (50%) individuals
treated early had subnormal results and neither person
had pathological results. Three out of 9 patients (33.3%)
from the later treatment groups had subnormal results
and 5 out of 9 patients (55.6%) had pathological findings.
In the same study all early treatment patients had mild
or no visual impairment (2/2), while in the later treat-
ment groups one of 9 patients (11.1%) had moderate im-
pairment and one out of 9 patients (11.1%) was blind.
All people treated asymptomatically had either normal
or subnormal (3/3) ocular fundi findings, and each pa-
tient in the later treatment group had either pathological
or severely pathological findings (9/9) [22]. Three studies
reported on retinopathy [13, 24, 26]. Two of the 3 stud-
ies found less retinopathy in the early treatment group
(0–33.3%, 0/1 and 2/6) compared to 75–90% (6/8 and 9/
10) showing mild to full retinopathy in the late treat-
ment group. One study found 100% retinopathy in the
early treatment group, though this group only included
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Table 2 Outcomes of included studies
Study Mortality Cardiac problems Liver problems Other
Immonen 2016 [24] Asymptomatic screened: 0/1
Symptomatic clinical: 6/15 (40%)
Age at death for 5/6 mean
8.5 m. Median 5 m (range 3 m-2y)
Cardiomyopathy at
diagnosis
Asymptomatic screened:
0/1
S clinical 6/10 (60%)
Cardiomyopathy at the
end of study period:
Asymptomatic screened:
0/1
S clinical 4/10 (40%)
NR Retinopathy
Asymptomatic screened: 0/1
S Clinical: Mild: 7/10 (70%)
Moderate: 1/10 (10%)
Yes: 1/10 (10%) No: 1/10 (10%)
Neuropathy
Asymptomatic screened: 0/1
(not detected)
S clinical: Mild: 2/9 (22.2%),
Moderate: 1/9 (11.1%), None:
2/9 (22.2%),
Not detected: 4/9 (44.4%)
Sperk 2010 [9] Asymptomatic screened: 1/3
(33.3%)
LCHADD patient, age at death:
3 months
Symptomatic screened: 0/3
Cardiomyopathy
Asymptomatic screened:
0/3
Symptomatic screened:
2/3 (66.7%) both cases
MTPD
NR Motor/muscular problems
Asymptomatic screened: 0/3
Symptomatic screened: 1/3
(33.3%) MTPD case
Hypoglycaemia
Asymptomatic screened: 1/3
(33.3%) LCHADD case
Symptomatic screened:
3/3 (100%)
Karall 2015 [13] NR Cardiomyopathy
Asymptomatic screened:
1/6 (16.7%), median age
4months
Symptomatic screened:
1/3 (33%), median age 9
months
Pre-NBS clinical: 3/3
(100%), median age 23
months (range 3–156
months)
FN NBS clinical: 2/2
(100%), median age 4.5
months (range 4–5
months)
Hepatopathy
Asymptomatic screened:
1/6 (16.7%), neonatally
Symptomatic screened:
0/3
Pre-NBS clinical: 2/3
(66.7%), median age 13
months (range 3–23
months)
FN NBS clinical: 2/2
(100%), median age 4.5
months (range 4–5
months)
Retinopathy
Asymptomatic screened: 2/6
(33.3%), median age of onset 53
months (range 50–56 months)
Symptomatic screened: 1/3 (33.3%),
median age of onset 39 months
Pre-NBS clinical: 3/3 (100%), median
age of onset 24 months
(range 23–108 months)
FN NBS clinical: 2/2 (100%), median
age of onset 40 months
(range 38–42 months)
Motor/muscular problems
Psychomotor developmental
normal in all patients
Spiekerkoetter 2009 [6] Screened: 2/10 (20%), both
MTPD, age at death median
5.5 days (range 3–8 days)
Clinical: 6/17 (35.3%),
3 LCHADD, 3 MTPD; age
at death median ~ 2 months
(range 2 days – 4 years)
Cardiomyopathy
Screened: 4/10 (40%)
1 LCHADD, 3 MTPD
Clinical: 8/17 (47%)
7 LCHADD, 1 MTPD
Arrhythmias
Not reported in screened
group.
Clinical: 1/17 (5.9%)
Reye syndrome
Screened: 3/10 (30%)
1 LCHADD, 2 MTPD
Clinical: 6/17 (35.3%)
All LCHADD
Retinopathy
Screened: NR
Clinical: 6/17 (35.3%) 5 LCHADD,
1 MTPD
Neuropathy
Screened: NR
Clinical: 3/17 (17.7%) 2 LCHADD,
1 MTPD
Hypotonia/Myopathy
Screened: 4/10 (40%) 2 LCHADD,
2 MTPD
Clinical: 14/17 (82.4%) 12 LCHADD,
2 MTPD
Hypoglycaemia
Screened: 4/10 (40%) 3 LCHADD,
1 MTPD
Clinical: 15/17 (83.2%) 13 LCHADD,
2 MTPD
Boese 2016 [25] NR NR NR Best corrected visual acuity visit 1
Screened: 4/7 (57.1%) Central
Steady and Maintained (CSM)
(1 symptomatic case was CMS;
3 LCHADD)
Clinical 4/14 (28.6%) CSM
Best corrected visual acuity visit 2
Screened: 0/7 CSM
Clinical: 2/17 CSM (11.8%)
(1 LCHADD, 1 MTPD)
Vision visit 1 (calculated by reviewers)
Screened: 7/7 (100%) normal
Clinical: 14/14 (100%) normal
Vision visit 2 (calculated by reviewers)e
Screened: 7/7 (100%) normal
Clinical: 2/14 impaired (14.3%)
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Table 2 Outcomes of included studies (Continued)
Study Mortality Cardiac problems Liver problems Other
> 1 episode of rhabdomyolysis
Screened: 6/7 (85.7%)
Clinical: 13/13 (100%)
Hypoglycaemia
All LCHADD clinical cases presented
with hypoketotic hypoglycaemia
De Biase 2017 [26] NR Arrhythmias
Asymptomatic screened:
0/1
Symptomatic screened:
0/2
Symptomatic clinical: 1/2
(50%), 1 LCHADD
NR Retinopathy
Asymptomatic screened:
1/1 (100%), 1 LCHADD
Symptomatic screened:
1/2 (50%), 1 LCHADD
Symptomatic clinical: 2/2
(100%), 2 LCHADD
Neural problems
Asymptomatic screened: 0/1
Symptomatic screened: 0/2
Symptomatic clinical: 1/2
(50%), 1 LCHADD
Myoglobinuria
Asymptomatic screened: 0/1
Symptomatic screened: 0/2
Symptomatic clinical: 1/2
(50%), 1 LCHADD
Hypoglycaemia at diagnosis
Asymptomatic screened: 0/1
Symptomatic screened 2/2
(100%), 1 LCHADD, 1 MTPD
Symptomatic clinical: 1/2
(50%), 1 LCHADD
Gillingham 2017 [27] NR Cardiac complications
Asymptomatic screened:
0/7
Symptomatic clinical: 3/5
(60%), all 3 LCHADD
NR NR
Kang 2018 [28] Asymptomatic screened:
1/1 (100%)
Age at death: 49 days
Symptomatic clinical:
2/6 (33.3%)
Median age at death
(range): 6.5 days (4–9 days)
NR NR NR
Lund 2012 [15] Asymptomatic: 0/3
Symptomatic clinical:
1/2 (50%)
Age at death: 4 months
Cardiomyopathy
Asymptomatic screened:
0/3
Symptomatic clinical: 2/2
(100%)
Hepatopathy
Asymptomatic screened:
0/3
Symptomatic clinical: 1/2
(50%)
NR
Sykut-Cegielska
2011 [29]
Asymptomatic screened:
1/15 (6.7%)
Age at death: 7 days
Symptomatic clinical:
19/44 (43%)
Age at death: Mean
23.95 m; median 6 m
(range 4d-10y1m)
NR NR NR
Swedish
Cohort
studies
Fahnehjelm
2008 [21]
NR NR NR Visual problems
ERG findings
Asymptomatic screened:
Abnormal: 0/1 Pathological: 0/1
S clinical Abnormal: 2/4 (50%)
Pathological: 2/4 (50%)
SS clinical: Abnormal: 1/5 (20%)a
Pathological: 4/5 (80%)
Photophobia
Asymptomatic screened: 1/1 (100%)
S clinical: 3/4 (75%)
SS clinical: 4/4 (100%)b
Nyctalopia
Asymptomatic screened: 0/1
S clinical: 0/4
Fraser et al. Orphanet Journal of Rare Diseases          (2019) 14:258 Page 10 of 18
one person. This compares to 75% retinopathy in the
later treatment group (3 out of 4 patients).
Neurological problems
Neurological problems were reported in 4 studies
[6, 22, 24, 26]. The reported outcomes were epilepsy,
neuropathy and neurological symptoms. There were no
instances of any neurological problems in any of the
people who were treated early (n = 15 across the studies)
compared to problems in every late treatment group [10/
36 (27.7%) ranging from 17.7 to 33.3%].
Motor and muscular problems
Muscular and motor problems were reported in six
studies [6, 9, 13, 21, 25, 26]. The studies reported on
psychomotor development, myopathy, episodes of
Table 2 Outcomes of included studies (Continued)
Study Mortality Cardiac problems Liver problems Other
SS clinical: 2/4 (50%)c
Psychomotor development
Asymptomatic screened:
Developmental delay
(DD): 0/1 Severe DD: 0/1
S clinical: DD: 1/4 (25%)
Severe DD: 0/4
SS clinical: DD: 3/5 (60%)
Severe DD: 1/5 (20%)
Neonatal hypoglycaemia
Asymptomatic screened: 0/1
S clinical: 3/4 (75%)
SS clinical: 4/5: (80%)
Fahnehjelm
2016 [22]
NR NR NR Visual problems
ERG findings
Asymptomatic screened:
Subnormal: 1/2d (50%)
Pathological: 0/2
S clinical: Subnormal: 2/4
(50%) Pathological: 1/4 (25%)
SS clinical: Subnormal: 1/5
(20%) Pathological: 4/5 (80%)
Best corrected visual acuity
Asymptomatic screened:
no/mild visual impairment: 2/2 (100%)
Missing data 1/3 (33.3%)
S clinical: Moderate impairment:
1/4 (25%) No/mild impairment: 3/4 (75%)
SS clinical: Blindness: 1/4
(25%) No/mild impairment:
2/4 (50%) Missing data: 1/5 (20%)
Ocular fundi
Asymptomatic screened:
Normal: 1/3 (33.3%) Subnormal: 2/3 (66.7%)
S clinical: Pathological: 4/4 (100%)
SS clinical: Pathological 4/5 (80%)
Severely pathological 1/5 (20%)
Neural problems
Epilepsia
Asymptomatic screened: 0/3
S clinical: 1/4 (25%)
SS clinical: 2/5 (40%)
Hypoglycaemia
Asymptomatic screened: 1/3 (33.3%)
S clinical: 3/4 (75%)
SS clinical: 4/5 (80%)
Haglind
2013 [23]
NR NR NR Hypoglycaemia
Asymptomatic screened: 0/1
S clinical: 3/4 (75%)
SS clinical: 4/5: (80%)
DD Developmental delay; ERG electroretinography test S symptomatic; SS severe symptomatic
aProgressive subnormal
bNo information on one person
cFurther visual measures are provided in the paper
d1 no ERG
eThe World Health Organization established criteria for low vision using the LogMAR scale. Low vision is defined as a best-corrected visual acuity worse
than 0.5 LogMAR but equal or better than 1.3 LogMAR in the better eye. Blindness is defined as a best-corrected visual acuity worse than 1.3 LogMAR
in the better eye. Normal defined as above 0.5
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rhabdomyolysis, and myoglobinuria. There were fewer
motor and muscular problems in all early treatment
groups compared to the late treatment groups across all
studies (0–40%, 5 out of a total of 17 in the early group,
compared to 25–82.4%, 21 out of a total of 38 in the late
group).
Pre-specified follow up comparisons
The following three follow up analyses considered differ-
ent subsets of the available individual patient data. Results
of the follow up analyses are presented in Figs. 3, 4 and 5
and in Additional file 5.
Asymptomatically vs symptomatically detected patients
Individual patient data reported in eight papers were
used for the follow up comparisons of outcomes in
asymptomatically vs symptomatically detected patients
[15, 21–24, 27–29]. Details are provided in Fig. 3 and
Additional file 5. One patient group included cases diag-
nosed post mortem and cases with unknown method of
diagnosis within the group with symptoms at diagnosis.
For the purpose of these follow up analyses these cases
were excluded (n = 7) [29].
There were no significant differences in the incidence
of liver, visual, neurological, motor or muscular pro-
blemss between pre-symptomatically and symptomatic-
ally detected patients in the studies reporting data for
these outcomes [9, 13, 15, 21–26].
There was no significant difference in mortality rates in
5/6 analysed patient groups reporting on asymptomatic ver-
sus symptomatically detected patients [6, 9, 15, 24, 28] . In
the remaining study, significantly more deaths occurred in
the symptomatically presenting patients (19/44, median age
at death 1.82 years) than in the pre-symptomatically de-
tected patients (1/15, p = 0.01, age at death 7 days) [29].
There was no statistically significant difference in the
frequency of heart problems in 5/6 analysed patient
groups [9, 13, 15, 24, 26]. In one study, significantly
more cardiac complications occurred in the symptom-
atic group (3/5, median age at study end 9 years) than in
the asymptomatic group (0/7, p < 0.05, median age at
study end 17 years) [27].
Screened vs unscreened patients
Follow up analyses were undertaken to see how group-
ing people by whether they were detected through
screening (including cascade testing) or outside of
screening affected outcomes. Details are provided in
Fig. 4 and Additional file 5.
Among the five studies that reported on mortality
[6, 15, 24, 28, 29], no statistically significant differ-
ences were found between the screened and unscreened
groups in four studies [6, 15, 24, 28]. In the final study,
there were significantly fewer deaths in the screened
group (1/15, median age at death 7 days) than in the clin-
ically detected unscreened group (13/37, median age at
death 1.82 years, p < 0.05) [29].
Among the six studies reporting on heart problems
[6, 13, 15, 24, 26, 27], no statistically significant dif-
ferences were found between screened and unscreened
groups in four of the studies [6, 15, 24, 26]. In the
remaining two studies, one study found significantly fewer
cases of cardiomyopathy in the screened group (2/9, me-
dian age 5.06 years) compared to the clinically detected
unscreened group (5/5, median age 9.4 years, p = 0.02)
[13]. The second study found significantly fewer cardiac
complications in the screened group (0/7) compared to
the unscreened group (3/5, p < 0.05) [27].
Three studies reported on the incidence of liver
problems [6, 13, 15]. Two studies found no statisti-
cally significant differences between the screen-
detected and clinically detected unscreened groups
[6, 15]. In the remaining study, there were signifi-
cantly fewer cases of hepatopathy in the screen de-
tected group (1/9, median age 5.06 years) compared
to the unscreened clinical group (4/5, median age
9.4 years, p = 0.02) [13].
Visual problems
Six studies (from five cohorts) reported on eye problems
[13, 21, 22, 24–26]. Five of the six did not find a signifi-
cant difference between screen detected and clinically
detected groups. In one study, retinopathy was signifi-
cantly less common amongst screen detected individuals
(3/9, 100%) than clinically detected after screening indi-
viduals (5/5, 100%), p = 0.03 [13].
Motor and muscular problems
Four studies reported on motor and muscular prob-
lems [6, 21, 25, 26]. Three of these did not find a sig-
nificant difference between screen detected and
clinically detected groups. There were significantly
fewer cases of hypotonia/myopathy in the screen
detected group (4/10, 40%) compared to the clinically
detected after screening group (14/17, 82.4%) in the
remaining study, p = 0.03) [6].
Hypoglycaemia
Two studies explored hypoglycaemia (not as a present-
ing symptom), and are presented in [6, 22]. One of the 2
studies found a significant difference between screen de-
tected and clinically detected groups (p = 0.02) [6]. They
found 4 out of 10 (40%) cases in the screen detected
group compared to 15 out of 17 (88%) in the clinically
detected after screening group.
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Fig. 3 Forest plot showing mortality and incidence of cardiac and liver problems across symptomatically and asymptomatically detected patients
per study (follow up analysis 1)
Fraser et al. Orphanet Journal of Rare Diseases          (2019) 14:258 Page 13 of 18
Fig. 4 Forest plot showing mortality and incidence of cardiac and liver problems across screened and unscreened patients per study (follow up
analysis 2)
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3) asymptomatic screened, symptomatic screened, and
late clinically detected patients
Four studies were included in this follow up analysis
[6, 13, 25, 26] . Details are provided in Fig. 5 and
Additional file 5.
No statistically significant differences between groups
were found for mortality (1 study [6]), liver problems (2
studies [13, 26]), neurological problems (1 study [26]),
muscular/motor problems (1 study [26]) or hypoglycaemia
(1 study [26]).
Differences in the incidence of heart problems were
reported in two studies [13, 26]. There was a statistically
significant difference between group and cardiomyop-
athy incidence in one study (p < 0.05) [13]. This was
driven by a higher frequency of cardiomyopathy in the
late clinically diagnosed group (5/5, median age 12.2
Fig. 5 Forest plot showing mortality and incidence of cardiac and liver problems across symptomatic screened, asymptomatic screened and
symptomatic clinically diagnosed patients per study (follow up analysis 3)
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years) compared to the asymptomatic screened group
(1/6, median age 3.2 years). There was no statistically
significant difference in the incidence of arrhythmias be-
tween the three groups in the second study (p = 1) [26].
Visual problems
Three studies reported visual problems across the 3 separ-
ate groups [13, 25, 26]. There was no significant difference
in 2 studies. One study found a significant difference be-
tween the groups in terms of retinopathy: asymptomatic
screening group = 1/6 (16.7%), symptomatic screening
group = 1/3 (33.3%), late clinical detection group = 4/5
(80%), p = 0.05 [13]. No statistically significant differences
were observed in pairwise comparison. This may be due
to a lack of statistical power related to the small sample
sizes.
Discussion
We conducted a systematic review to examine the clinical
outcomes of people with LCHADD/MTPD who received
early dietary management following screening (universal
newborn screening, cascade testing or incidental detec-
tion) versus later dietary management following the pres-
entation of symptoms (either before or after the screening
period). We included 13 articles, reporting on 11 patient
groups. The methodological quality of all of the included
studies was weak or moderate.
From our narrative synthesis there appear to be fewer
instances of heart and liver related problems in people
with LCHADD or MTPD who are diagnosed earlier
(either through newborn screening, cascade testing, or
incidental detection) than those diagnosed at a later age
(following symptomatic presentation). However, it is not
clear whether these differences are due to a beneficial ef-
fect of screening or biases in study design, and it is less
clear whether there is any reduction in mortality follow-
ing screen-detection. Mortality may occur earlier in
those the early screen detected group. This may be due
to these newborns being symptomatic at diagnosis and
having a more severe form of the disease. 6/13 studies
[6, 9, 15, 24, 28, 29] were concerned with the health ben-
efits of treatment during life, and did not report on mor-
tality. Therefore, we do not have a complete picture on
whether the treatments in those studies would have had
an effect on mortality. We undertook additional pre-
specified follow up analyses to explore differences in
outcomes between 1) asymptomatically vs symptomatic-
ally detected patients, (2) screened vs unscreened patients
and (3) people who were asymptomatic at screening vs
those who were symptomatic at screening vs those who
were clinically detected in the absence of screening or
who were clinically detected following false negative
screening results. The majority of studies did not show a
statistically significant difference between any of the
groups across the three comparisons. Across follow up
analyses 1 and 2 (comprising 58 individual comparisons in
total), eight comparisons reached statistical significance
across four studies [6, 13, 27, 29] (see Additional file 5 for
details). For follow up analysis 3, only one (out of 10) 3-
way comparisons performed was statistically significant
when the group who presented with symptoms before
screening took place were analysed separately, with
greater instances of cardiomyopathy in the late clinical
group than in the earlier asymptomatic screened group
[13]. The limited number of statistically significant results
in the follow up comparisons performed may be due to
the low number of patients per comparison group (1–44
patients per comparison group, the vast majority of groups
comprising less than 10 patients) resulting in low power
to reject a false null hypothesis. There are also inherent
biases in these analyses. Follow up analysis 1 comparing
asymptomatic (detected by newborn screening, cascade
testing or incidentally) cases versus cases with symptoms
at diagnosis (early or late symptomatic) reflects the way
the majority of the papers reported their data. This is the
comparison of most interest in assessing the benefits of
implementing screening. However, this comparison is
biased towards screening as the most severe cases with
symptoms before or at the time of newborn screening will
all be allocated to the ‘symptomatic’ group. Follow up ana-
lysis 2 comparing screened (asymptomatic or early symp-
tomatic) versus unscreened (early or late symptomatic)
cases is less biased due to the allocation of the severe early
presenting cases but is less applicable to the screening
question as in current practice; babies with symptoms be-
fore or at the time of newborn screening would receive
diagnostic testing anyway and would not benefit from
screening. Age may have been a confounding factor in this
follow up analysis as well. Those with more follow-up
have more time in which an event can be recorded in the
study, with events missed in those with insufficient follow
up. Age at the time of the study was reported in eight out
of the 10 studies [9, 13, 21–29]. In seven of those
eight, the patients in the ‘screened’ group were consid-
erably younger than the patients in the ‘unscreened’
groups (median ages of 2–10 years in the ‘screened’
groups compared to median ages between 19 and 22
years in the ‘unscreened’ groups [13, 21–29]. Most of
the ‘unscreened’ group were cases ascertained prior to
the introduction of universal newborn screening, so
their disease may have progressed further than in the
screen-detected cases. By doing follow up analysis 3,
comparing symptomatic screened, asymptomatic
screened and clinically detected patients (either un-
screened or false negative screening test), we were able
to reduce some of these biases, however, very few
studies reported these data and sample sizes per group
were very small.
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A related review we undertook highlighted an issue in
the indexing of some search terms in MEDLINE. The
phrase “inborn errors of metabolism” had not been
indexed as a MeSH heading, so further searches were
done using this phrase as a key word search. Only one
additional paper was identified that was relevant for this
review.
Our systematic review has a number of strengths. To
our knowledge, this is the first systematic review com-
paring the outcomes of LCHADD and MTPD patients
following pre-symptomatic detection or clinical detec-
tion after presenting with symptoms. We conducted a
wide-ranging exhaustive search with no limits on date or
language, independent literature screening and quality
appraisal were undertaken by two reviewers, and all data
extraction forms were checked by a second reviewer.
However, there are also some limitations. Although we
did not exclude studies on the basis of language, the
search terms were in English so may have missed papers
in other languages.
Drawing conclusions from the follow up analyses should
be interpreted with caution due to the small sample sizes.
This review considers the statistical significance in the ob-
served comparisons, but given the very few number of pa-
tients who have these disorders, it is important to also
consider the clinical significance. Avoiding cardiomyop-
athy and hepatomegaly is of serious clinical importance to
patients. On the other hand, enforcing a restricted diet on
patients who have screened positive but who remain
asymptomatic and may have never gone on to become
symptomatic, may seriously affect their quality of life.
Evidence is still very limited and at risk of bias. Further
investigation is needed regarding whether the cases of
LCHADD and MTPD detected by screening represent
the same spectrum of disease as those detected clinically,
and whether all screen-detected babies would go on to
become symptomatic. Confounding factors such as age
at time of study, follow-up time, possible repetition of
patients across cohorts, genotype and severity of disease
must all be considered. Analyses of genotype phenotype
correlations might be of assistance in the future. Like-
wise, large international collaborations may help provide
a clearer picture on whether pre-symptomatic treatment
results in better outcomes.
Conclusions
There is some evidence to suggest that pre-symptomatic
dietary management may help delay or prevent the onset
of some LCHADD and MTPD related long-term com-
plications. However, studies have not been large enough
to show any consistent significant benefits, and many
confounding factors such as genotype, disease severity,
age at diagnosis, and follow-up time between ‘early’ and
‘late’ treated groups have not been accounted for. An
internationally collaborative research effort is needed to
fully examine the risks and the benefits to pre-emptive
dietary management with particular attention being paid
to disease severity and treatment group.
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